Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
## Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be increased as needed. Usual doses range from 40 mg to 80 mg daily. Maximum recommended daily oral dose is 80 mg. Maximum recommended daily IV dose is 80 mg over 2 hours.
## Pediatric Dosing
* **GERD (ages 5-16 years):**
* **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Symptomatic GERD:** 20 mg orally once daily for up to 8 weeks.
* Dosing for children younger than 5 years has not been established.
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose is 40 mg orally.
* **Renal Impairment:** No dose adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
* **Serious:** Acute interstitial nephritis, Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia, fundic gland polyps.
## Key Drug Interactions
* **Drugs affected by gastric pH:** Absorption may be affected (e.g., ketoconazole, itraconazole, posaconazole, iron salts, vitamin B12).
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential for increased levels of drugs metabolized by this enzyme (e.g., clopidogrel, warfarin, phenytoin, diazepam).
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremors, muscle cramps, seizures).
* Monitor for signs and symptoms of C. difficile infection.
* Consider bone mineral density monitoring in patients at risk for osteoporosis with prolonged therapy.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* IV administration should be over at least 15 minutes.
* Long-term PPI use is associated with increased risk of fractures, C. difficile infection, and hypomagnesemia. Assess the need for continued therapy periodically.
***
*Disclaimer: This information is intended for healthcare professionals and should not replace professional judgment. Always consult the most current prescribing information and relevant guidelines before making treatment decisions.*
